ArticleBMC psychiatry2026
Antipsychotic selection in combination with electroconvulsive therapy for acute schizophrenia: differential efficacy and safety profiles from a real world study.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundElectroconvulsive therapy (ECT) used in combination with antipsychotic medications is an important therapeutic strategy for the management of acute episodes of schizophrenia. However, direct comparisons of the efficacy and safety of different antipsychotic agents when administered alongside ECT remain limited.
methodsA total of 465 individuals with acute-phase schizophrenia were included in the analysis. All participants underwent six sessions of bitemporal ECT delivered over a two-week period. The primary endpoint was the reduction rate of the Positive and Negative Syndrome Scale total score (PANSS-TRR). Secondary outcomes included reduction rates for the PANSS positive symptom subscale (PANSS-PRR), negative symptom subscale (PANSS-NRR), and general psychopathology subscale (PANSS-GRR). Treatment safety was evaluated using the UKU Side Effect Rating Scale (UKU) and the Gastrointestinal Symptom Rating Scale (GSRS). To reduce subjectivity, we conducted reliability training.
resultsSignificant symptomatic improvement was observed in all treatment groups following the ECT course. After adjustment for confounding variables, and applying inverse probability of treatment weighting (IPTW) with Bonferroni correction, compared with ECT alone, clozapine-ECT and sulpiride-ECT showed statistically significant advantages in overall symptom reduction (PANSS-TRR). For positive symptom reduction (PANSS-PRR), clozapine-ECT, quetiapine-ECT, risperidone-ECT, and ziprasidone-ECT were associated with significantly greater improvements. No combination demonstrated statistically significant superiority over ECT alone for negative symptoms or general psychopathology after correction. Pairwise comparisons suggested that amisulpride-ECT was associated with smaller improvements in PANSS-TRR compared with clozapine-ECT, risperidone-ECT, and quetiapine-ECT.
conclusionIn this observational study of patients with acute phase schizophrenia, the comparative effectiveness and tolerability of antipsychotic medications combined with ECT appeared to differ depending on the specific agent used. These preliminary observations require confirmation in randomized controlled trials before guiding individualized treatment selection.
trial registrationChinese Clinical Trial Registry: ChiCTR2500101865. Registered on 30 April 2025. (retrospectively registered). CLINICAL TRIAL NUMBER: ChiCTR2500101865.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.